Abstract
Virus vector-mediated gene transfer has been developed as a treatment for cystic fibrosis (CF) airway disease, a lethal inherited disorder caused by somatic mutations in the cystic fibrosis transmembrane conductance regulator gene. The pathological proinflammatory environment of CF as well as the naïve and adaptive immunity induced by the virus vector itself limits the effectiveness of gene therapy for CF airway. Here, we report the use of an HDAC inhibitor, valproic acid (VPA), to enhance the activity of the regulatory T cells (Treg) and to improve the expression of virus vector-mediated gene transfer to the respiratory epithelium. Our study demonstrates the potential utility of VPA, a drug used for over 50 years in humans as an anticonvulsant and mood-stabilizer, in controlling inflammation and improving the efficacy of gene transfer in CF airway.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Massie J, Curnow L, Gaffney L, Carlin J, Francis I . Declining prevalence of cystic fibrosis since the introduction of newborn screening. Arch Di Child 2010; 95: 531–533.
Koehler DR, Downey GP, Sweezey NB, Tanswell AK, Hu J . Lung inflammation as a therapeutic target in cystic fibrosis. Am J Respir Cell Mol Biol 2004; 31: 377–381.
Rowe SM, Miller S, Sorscher EJ . Cystic fibrosis. N Engl J Med 2005; 352: 1992–2001.
Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB, Ghnaim H et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995; 152 (6 Pt 1): 2111–2118.
Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066–1073.
Griesenbach U, Geddes DM, Alton EW . Gene therapy progress and prospects: cystic fibrosis. Gene Therapy 2006; 13: 1061–1067.
Ziady AG, Davis PB . Current prospects for gene therapy of cystic fibrosis. Curr Opin Pharmacol 2006; 6: 515–521.
Prickett M, Jain M . Gene therapy in cystic fibrosis. Transl Res 2013; 161: 255–264.
Rich DP, Anderson MP, Gregory RJ, Cheng SH, Paul S, Jefferson DM et al. Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature 1990; 347: 358–363.
Drumm ML, Pope HA, Cliff WH, Rommens JM, Marvin SA, Tsui LC et al. Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell 1990; 62: 1227–1233.
Yang Y, Li Q, Ertl HC, Wilson JM . Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004–2015.
Wilson JM . Adeno-associated virus and lentivirus pseudotypes for lung-directed gene therapy. Proc Am Thorac Soc 2004; 1: 309–314.
Yang Y, Su Q, Wilson JM . Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J Virol 1996; 70: 7209–7212.
Jooss K, Turka LA, Wilson JM . Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Therapy 1998; 5: 309–319.
Sack BK, Herzog RW . Evading the immune response upon in vivo gene therapy with viral vectors. Curr Opin Molr Ther 2009; 11: 493–503.
McKinley L, Logar AJ, McAllister F, Zheng M, Steele C, Kolls JK . Regulatory T cells dampen pulmonary inflammation and lung injury in an animal model of pneumocystis pneumonia. J Immunol 2006; 177: 6215–6226.
Wilson MS, Taylor MD, Balic A, Finney CA, Lamb JR, Maizels RM . Suppression of allergic airway inflammation by helminth-induced regulatory T cells. J Exp Med 2005; 202: 1199–1212.
Zhang H, Xiao Y, Zhu Z, Li B, Greene MI . Immune regulation by histone deacetylases: a focus on the alteration of FOXP3 activity. Immunol Cell Biol 2012; 90: 95–100.
Du T, Nagai Y, Xiao Y, Greene MI, Zhang H . Lysosome-dependent p300/FOXP3 degradation and limits T cell functions and enhances targeted therapy against cancers. Exp Mol Pathol 2013; 95: 38–45.
van Loosdregt J, Vercoulen Y, Guichelaar T, Gent YY, Beekman JM, van Beekum O et al. Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. Blood 2010; 115: 965–974.
Song X, Li B, Xiao Y, Chen C, Wang Q, Liu Y et al. Structural and biological features of FOXP3 dimerization relevant to regulatory T cell function. Cell Rep 2012; 1: 665–675.
Saouaf SJ, Li B, Zhang G, Shen Y, Furuuchi N, Hancock WW et al. Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp Mol Pathol 2009; 87: 99–104.
Snouwaert JN, Brigman KK, Latour AM, Malouf NN, Boucher RC, Smithies O et al. An animal model for cystic fibrosis made by gene targeting. Science 1992; 257: 1083–1088.
Nathan C . Neutrophils and immunity: challenges and opportunities. Nate Rev Immunol 2006; 6: 173–182.
Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 2009; 138: 1019–1031.
Moreira JM, Scheipers P, Sorensen P . The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer 2003; 3: 30.
Brogdon JL, Xu Y, Szabo SJ, An S, Buxton F, Cohen D et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 2007; 109: 1123–1130.
Fan S, Maguire CA, Ramirez SH, Bradel-Tretheway B, Sapinoro R, Sui Z et al. Valproic acid enhances gene expression from viral gene transfer vectors. J Virol Methods 2005; 125: 23–33.
Stedt H, Samaranayake H, Pikkarainen J, Maatta AM, Alasaarela L, Airenne K et al. Improved therapeutic effect on malignant glioma with adenoviral suicide gene therapy combined with temozolomide. Gene Therapy 2013; 20: 1165–1171.
Ferrari S, Griesenbach U, Geddes DM, Alton E . Immunological hurdles to lung gene therapy. Clin Exp Immunol 2003; 132: 1–8.
Zhang Y, Chirmule N, Gao G, Wilson J . CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells. J Virol 2000; 74: 8003–8010.
Rudensky AY, Campbell DJ . In vivo sites and cellular mechanisms of T reg cell-mediated suppression. J Exp Med 2006; 203: 489–492.
Lahat N, Rivlin J, Iancu TC . Functional immunoregulatory T-cell abnormalities in cystic fibrosis patients. J Clin Immunol 1989; 9: 287–295.
Curotto de Lafaille MA, Kutchukhidze N, Shen S, Ding Y, Yee H, Lafaille JJ . Adaptive Foxp3+ regulatory T cell-dependent and -independent control of allergic inflammation. Immunity 2008; 29: 114–126.
Conese M, Copreni E, Di Gioia S, De Rinaldis P, Fumarulo R . Neutrophil recruitment and airway epithelial cell involvement in chronic cystic fibrosis lung disease. J Cystic Fibrosis 2003; 2: 129–135.
Cohen TS, Prince A . Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 2012; 18: 509–519.
Xiao Y, Li B, Zhou Z, Hancock WW, Zhang H, Greene MI . Histone acetyltransferase mediated regulation of FOXP3 acetylation and Treg function. Curr Opin Immunol 2010; 22: 583–591.
Li B, Saouaf SJ, Samanta A, Shen Y, Hancock WW, Greene MI . Biochemistry and therapeutic implications of mechanisms involved in FOXP3 activity in immune suppression. Curr Opin Immunol 2007; 19: 583–588.
Li B, Greene MI . FOXP3 actively represses transcription by recruiting the HAT/HDAC complex. Cell Cycle 2007; 6: 1432–1436.
Richards H, Williams A, Jones E, Hindley J, Godkin A, Simon AK et al. Novel role of regulatory T cells in limiting early neutrophil responses in skin. Immunology 2010; 131: 583–592.
D'Alessio FR, Tsushima K, Aggarwal NR, West EE, Willett MH, Britos MF et al. CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury. J Clin Invest 2009; 119: 2898–2913.
Conese M, Ascenzioni F, Boyd AC, Coutelle C, De Fino I, De Smedt S et al. Gene and cell therapy for cystic fibrosis: from bench to bedside. J Cystic Fibrosis 2011; 10 (Suppl 2): S114–S128.
Limberis MP, Wilson JM . Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered. Proc Natl Acad Sci USA 2006; 103: 12993–12998.
Limberis MP, Vandenberghe LH, Zhang L, Pickles RJ, Wilson JM . Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro. Mol The 2009; 17: 294–301.
New M, Olzscha H, La Thangue NB . HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol 2012; 6: 637–656.
Price A, Limberis M, Gruneich JA, Wilson JM, Diamond SL . Targeting viral-mediated transduction to the lung airway epithelium with the anti-inflammatory cationic lipid dexamethasone-spermine. Mol Ther 2005; 12: 502–509.
Acknowledgements
We thank the members of the Vector Core, Animal Models Core and Cell Morphology Core of the Gene Therapy Program at the University of Pennsylvania for assistance with these studies. Flow cytometry was performed at the Abramson Cancer Center Flow Cytometry and Cell Sorting Shared Resource, a member of Path BioResource, in the Perelman School of Medicine of the University of Pennsylvania, which was established in part by equipment grants from the NIH Shared Instrument Program, and receives support from NIH P30 CA016520 from the National Cancer Institute. This work was supported by grants from the National Institutes of Health grants P30DK047757 (Pilot grant) and P01AI073489.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Nagai, Y., Limberis, M. & Zhang, H. Modulation of Treg function improves adenovirus vector-mediated gene expression in the airway. Gene Ther 21, 219–224 (2014). https://doi.org/10.1038/gt.2013.78
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2013.78